Mode
Text Size
Log in / Sign up
N/A N=32 Randomized Treatment

CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder

Opioid-use Disorder · Medication Adherence · Health Care Utilization

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
May 2023
Primary outcome: Primary: Number of Missed Medication Doses - Past 30 Days — 3.13; 2.81; 3.71; 2.25 Number of missed doses — p=0.17

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Behavioral Activation (BA) Therapy (Behavioral); Substance Abuse and Health Navigation Counseling (Behavioral); Medications for Opioid Use Disorder (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Brown University
Primary completion
Feb 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Missed Medication Doses - Past 30 Days
3.13; 2.81; 3.71; 2.25; 1.19; 1.69 0.17
PRIMARY
Number of Missed Medication-related Visits - Past 30 Days
1.13; 0.94; 0.14; 0.25; 0.06; 0.06 0.90
SECONDARY
Fentanyl and Opiate-positive Urine Toxicology Screen
6; 3; 3; 4; 2; 3 0.02 sig

Summary

This study seeks primarily to test, in a two-arm randomized controlled trial (RCT), the feasibility, acceptability, and preliminary efficacy of CoMBAT OUD, an intervention that integrates Behavioral Activation (BA) and substance abuse and health navigation counseling for individuals who are receiving medications for opioid use disorder (i.e., methadone; suboxone) to help them improve engagement in care and opioid use treatment outcomes. Participants will be randomized 1:1 to two arms: (1) the CoMBAT intervention (2 sessions of substance abuse and health navigation counseling + 8 sessions of BA counseling); or the (3) the standard of care (SOC) comparison condition, including two equivalent substance abuse and health navigation counseling. Participants will be followed for 6 months post-randomization, with assessments at months 3 and 6.

Eligibility Criteria

Inclusion Criteria

  • Age 18 years or older
  • Initiated medications for opioid use >= 30 day prior to screening
  • Current depressive symptoms
  • Plans to stay in Rhode Island or Massachusetts for at least 6-months
  • Able to read, speak, and understand English
  • Willing and able to provide informed consent

Exclusion Criteria

  • Does not plan to continue taking medications for opioid use disorder
  • Unable to provide informed consent due to severe mental or physical illness, or substance intoxication at the time of interview
  • Discovery of active suicidal ideation at the time of interview
  • In the second or third trimester of pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04240093). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search